Patrick Connerty

Kensington, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity.

Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity.

Journal: Blood advances

Published: December 08, 2025

Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.

Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.

Journal: Blood advances

Published: December 08, 2025

The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.

The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.

Journal: British journal of haematology

Published: August 14, 2025

Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in xenograft models of paediatric acute myeloid leukaemia.

Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in xenograft models of paediatric acute myeloid leukaemia.

Journal: British journal of haematology

Published: September 26, 2024

CRISPR-Cas9 Genome-Wide Screening in Paediatric Cancer: Functional Genomics for Target Discovery and the Improvement of Existing Therapies.

CRISPR-Cas9 Genome-Wide Screening in Paediatric Cancer: Functional Genomics for Target Discovery and the Improvement of Existing Therapies.

Journal: Medicinal research reviews

Published: September 13, 2024

TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells.

TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells.

Journal: Nature communications

Published: March 15, 2024

Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.

Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.

Journal: Science translational medicine

Published: May 17, 2023

The tip of the iceberg-The roles of long noncoding RNAs in acute myeloid leukemia.

The tip of the iceberg-The roles of long noncoding RNAs in acute myeloid leukemia.

Journal: Wiley interdisciplinary reviews. RNA

Published: March 27, 2023

Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells.

Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells.

Journal: Frontiers in oncology

Published: November 01, 2021

Development of siRNA-Loaded Lipid Nanoparticles Targeting Long Non-Coding RNA LINC01257 as a Novel and Safe Therapeutic Approach for t(8;21) Pediatric Acute Myeloid Leukemia.

Development of siRNA-Loaded Lipid Nanoparticles Targeting Long Non-Coding RNA LINC01257 as a Novel and Safe Therapeutic Approach for t(8;21) Pediatric Acute Myeloid Leukemia.

Journal: Pharmaceutics

Published: August 17, 2021

Long Non-coding RNAs: Major Regulators of Cell Stress in Cancer.

Long Non-coding RNAs: Major Regulators of Cell Stress in Cancer.

Journal: Frontiers in oncology

Published: December 02, 2019

Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia.

Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia.

Journal: Leukemia

Published: July 04, 2019

Showing 1-12 of 17

Last Updated: 09/26/2026